Getty ImagesRegeneron is acquiring Checkmate Pharmaceuticals and entered a clinical trial collaboration with SpringWorks Therapeutics to evaluate REGN5458 in multiple myeloma in combination with nirogacestat.
Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
bluebird bio announced that it expected to file three applications for regulatory approval by the end of 2019.
A look at five biotech companies in the cancer market and their upcoming releases at the 2017 American Society of Clinical Oncology (ASCO).
Danish biotech Genmab, which has seen its shares rocket 163 percent this year, is set for further gains as new research data showed increased potential for its Darzalex blood cancer […]
First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who […]
U.S. regulators have approved an experimental treatment from Johnson & Johnson that may offer hope to multiple myeloma patients who have run out of other options against the blood cancer. […]
Novartis AG said on Friday it received European Union approval for Farydak, a treatment for multiple myeloma that the company said gives new options for adult patients whose disease has […]